Ignite Creation Date:
2025-12-25 @ 3:33 AM
Ignite Modification Date:
2026-04-07 @ 4:38 AM
Study NCT ID:
NCT07160205
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-08
First Post:
2025-08-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Sponsor:
Restem, LLC.
Organization:
Study Overview
Official Title:
A Phase 2-Phase 3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to Assess the Safety and Efficacy of Allogeneic ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM)
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IIMPACT
Brief Summary:
The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell (ULSC) product performs when treating Dermatomyositis/Polymyositis (DM/PM), also known as idiopathic inflammatory myopathy (IIM) in adults. It will assess safety and efficacy in relieving symptoms of DM/PM with ULSC administered in three intravenous (IV) doses of 150 million cells per dose.
The main questions that this study plans to answer are:
* Is ULSC as safe as placebo (a look-alike saline without cells) in repeated IV infusion?
* Does ULSC improve symptoms of DM/PM after three doses? Researchers will compare ULSC to placebo and evaluate changes from baseline (before first dose) to after each dose and after all three doses are completed per treatment study period.
* For participants undergoing steroid (e.g., prednisone) therapy for DM/PM, does ULSC allow their steroid dose to be reduced? Does ULSC reduce need for rescue therapy?
Participants will have been diagnosed with either DM or PM:
* Diagnosed according to the EULAR/ACR 2017 Classification Criteria for idiopathic inflammatory myositis (IIM), which includes DM and PM.
* Positive for myositis-associated antibody or undergone evaluation to exclude mimics.
Participants in this study will:
* Participate for total of 25 months with 15 in-person clinic visits and 8 virtual visits on phone or video call.
* Receive both ULSC and placebo for a total of 6 IV infusions (260 mL) 3 months apart.
* Receive 3 doses of ULSC and 3 doses placebo in either of two sequences, as assigned: ULSC first and placebo second, or placebo first and ULSC second.
* If undergoing steroid therapy, will have steroid dose taper prescribing lower doses starting two weeks after the second infusion.
* Return for follow-up visits after each dose and up to 12 months after final dose.
* Have follow-ups including self-reported questionnaires, physical exam, muscle strength and endurance tests, blood tests, pulmonary function tests, and other assessments.
The main questions that this study plans to answer are:
* Is ULSC as safe as placebo (a look-alike saline without cells) in repeated IV infusion?
* Does ULSC improve symptoms of DM/PM after three doses? Researchers will compare ULSC to placebo and evaluate changes from baseline (before first dose) to after each dose and after all three doses are completed per treatment study period.
* For participants undergoing steroid (e.g., prednisone) therapy for DM/PM, does ULSC allow their steroid dose to be reduced? Does ULSC reduce need for rescue therapy?
Participants will have been diagnosed with either DM or PM:
* Diagnosed according to the EULAR/ACR 2017 Classification Criteria for idiopathic inflammatory myositis (IIM), which includes DM and PM.
* Positive for myositis-associated antibody or undergone evaluation to exclude mimics.
Participants in this study will:
* Participate for total of 25 months with 15 in-person clinic visits and 8 virtual visits on phone or video call.
* Receive both ULSC and placebo for a total of 6 IV infusions (260 mL) 3 months apart.
* Receive 3 doses of ULSC and 3 doses placebo in either of two sequences, as assigned: ULSC first and placebo second, or placebo first and ULSC second.
* If undergoing steroid therapy, will have steroid dose taper prescribing lower doses starting two weeks after the second infusion.
* Return for follow-up visits after each dose and up to 12 months after final dose.
* Have follow-ups including self-reported questionnaires, physical exam, muscle strength and endurance tests, blood tests, pulmonary function tests, and other assessments.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: